AstraZeneca Beats Expectations, But Focus Is on Busy Pipeline Ahead -- Market Talk

Dow Jones04-29 18:29

1029 GMT - AstraZeneca's first-quarter results beat consensus expectations at the top and bottom lines, but the focus is on a busy second half of the year for updates on its drug pipeline, Bank of America analysts say. The U.K. drugmaker reiterated its full-year guidance and delayed the release of results on two late-stage studies of Datroway in lung cancer to 2027 from the second half of this year, Bank of America says. Still, the second half should be a busy time for AstraZeneca in terms of clinical updates, the analysts say in a research note. Results of key studies evaluating treatments for lung cancer, breast cancer and amyloid cardiomyopathy should be published in the second half, with more to follow next year, they add. Shares fall 1.4%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 29, 2026 06:29 ET (10:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment